Glypican-3-Targeted
glypican-3 (GPC3)
hepatocellular carcinoma (HCC)
radioimmunotherapy
targeted α-therapy (TAT)
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
03
06
2021
revised:
08
10
2021
pubmed:
14
11
2021
medline:
6
7
2022
entrez:
13
11
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide, with limited therapeutic options for advanced disease. Targeted α-therapy is an emerging class of targeted cancer therapy in which α-particle-emitting radionuclides, such as
Identifiants
pubmed: 34772791
pii: jnumed.121.262562
doi: 10.2967/jnumed.121.262562
pmc: PMC9258570
doi:
Substances chimiques
GPC3 protein, human
0
Glypicans
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1038Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Am J Pathol. 2018 Sep;188(9):1973-1981
pubmed: 29935166
J Oncol. 2019 Sep 15;2019:4564707
pubmed: 31636665
Hepatology. 2019 Mar;69(3):1064-1074
pubmed: 30014489
Methods Enzymol. 2007;426:117-53
pubmed: 17697883
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Nucl Med. 2014 Dec;55(12):2032-7
pubmed: 25359880
Cancer Res. 2009 Jan 1;69(1):185-92
pubmed: 19118002
Blood. 2019 Oct 10;134(15):1247-1256
pubmed: 31395601
Exp Physiol. 2020 Sep;105(9):1459-1466
pubmed: 32666546
Eur J Haematol. 1989 Aug;43(2):150-7
pubmed: 2792322
Blood. 2013 May 2;121(18):3759-67
pubmed: 23471305
J Nucl Med. 2014 May;55(5):799-804
pubmed: 24627434
Nature. 1978 Jul 27;274(5669):365-6
pubmed: 307688
Oncotarget. 2016 Dec 27;7(52):86937-86947
pubmed: 27893426
Oncotarget. 2017 Apr 7;8(34):56311-56326
pubmed: 28915592
J Nucl Med. 2016 Oct;57(10):1569-1575
pubmed: 27230930
Molecules. 2020 Dec 22;26(1):
pubmed: 33374953
J Nucl Med. 2018 Jun;59(6):878-884
pubmed: 29545378
JAMA Oncol. 2018 Dec 1;4(12):1765-1772
pubmed: 30326033
J Am Chem Soc. 2013 Aug 28;135(34):12707-21
pubmed: 23901833
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Lab Anim (NY). 2005 Oct;34(9):39-43
pubmed: 16195737
Mol Cancer Ther. 2016 Oct;15(10):2422-2431
pubmed: 27535972
Sci Rep. 2021 Feb 12;11(1):3731
pubmed: 33580090
Nat Commun. 2015 Mar 11;6:6536
pubmed: 25758784
Clin Cancer Res. 2017 Aug 1;23(15):4335-4346
pubmed: 28364014
J Labelled Comp Radiopharm. 2020 Oct;63(12):502-516
pubmed: 32812275
J Am Chem Soc. 2012 May 23;134(20):8670-83
pubmed: 22540281
Semin Nucl Med. 2008 Sep;38(5):358-66
pubmed: 18662557
Clin Cancer Res. 2019 Aug 1;25(15):4723-4734
pubmed: 31064781
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4318-21
pubmed: 27476138
J Nucl Med. 2019 Sep;60(9):1293-1300
pubmed: 30850485
Anticancer Res. 2010 Dec;30(12):5055-61
pubmed: 21187490
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2019 Sep 10;11(9):
pubmed: 31510063
Biochem Biophys Res Commun. 2003 Jun 20;306(1):16-25
pubmed: 12788060
Sci Rep. 2017 Mar 31;7:45846
pubmed: 28361988
J Nucl Med. 2010 Feb;51(2):311-28
pubmed: 20080889